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Calreticulin (CRT) plays a role in the clearance of dying cells and has been implicated in autoimmunity. Recent
evidence indicates that cell surface CRT (csCRT) acts as a signal transducing receptor for the rheumatoid arthritis
(RA) shared epitope (SE). The SE binding site on CRT has been mapped to amino acid residues 217–223 in the
P-domain. Upon interaction with dendritic cells (DCs), the SE activates potent immune regulatory events. In CD8α+
DCs, which express higher abundance of csCRT, the SE inhibits the tolerogenic enzyme indoleamine 2,3 dioxygenase
with resultant inhibition of regulatory T (Treg) cell differentiation. In CD8α− DCs, the SE ligand increases secretion
of IL-6 and IL-23 and facilitates generation of Th17 cells, a T cell subset known to play a role in autoimmunity. On
the basis of these recent findings, we discuss the possibility that the csCRT may play a pathogenic role in RA by
transducing SE-activated Th17-polarizing signals.
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Introduction
Calreticulin (CRT) is a ubiquitous multifunc-
tional calcium-binding protein.1 Although origi-
nally characterized as an endoplasmic reticulum
molecular chaperone, more recently it has been
shown that extracellular CRT attaches to the sur-
face of many cells, where it is involved in sig-
nal transduction events associated with innate im-
munity, cell adhesion, and apoptosis.2–5 Because
CRT lacks a trans-membrane domain, CD91 (also
known as low-density lipoprotein receptor-related
protein 1 or 2 macroglobulin receptor) has been
proposed as a candidate anchoring receptor for
CRT.6
Cell surface CRT (csCRT) is an important innate
immune system receptor.7–12 It serves as the signal-
transducing receptor for members of the collectin
family, including C1q and mannose binding lectin.13
Collectins bind foreign organisms or apoptotic cells
through their globular heads, while their collagen-
like tails bind to csCRT, which leads to phagocytosis.
Different from the elimination of foreign organisms,
which are events associated with an intense inflam-
matory reaction,14 the safe clearance of apoptotic
cells critically depends on suppressing the inflam-
matory response.15 The decision of whether a pro-
or anti-inflammatory reaction should be activated
appears to depend on the presence or absence of a
second set of signals that are uniquely triggered by
apoptotic cells.16 Thus, csCRT plays a pivotal role in
the junction between tolerance and autoimmunity
because of its critical role in elimination of apoptotic
cells.17 Aberrant activation of the CRT-mediated
pathway can lead to autoimmunity, as exemplified
by conditions that involve defective CRT-mediated
clearance of apoptotic cells.18
Defective clearance of apoptotic cells has long
been postulated as a cause of autoantibody produc-
tion.18 Noningested apoptotic cells release danger
signals and provide self-antigens for aberrant pre-
sentation by dendritic cells (DCs). Consistent with
this model, both humans19 and mice20 deficient in
C1q develop a SLE-like disease. Donnelly et al.19
have reported impaired recognition of apoptotic
neutrophils by the C1q/CRT pathway in patients
with SLE. In this juncture, it should be mentioned
that CRT itself can be targeted by autoantibodies.20
It has been proposed that antigen-leak from apop-
totic cells account for this phenomenon.
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Little is known about the role of CRT in rheuma-
toid arthritis (RA). Although the protein has long
been known to be targeted by autoantibodies in RA,
the pathogenic significance of that immune recog-
nition is unclear. Moreover, the possibility that the
innate receptor function of CRT could play a role
has not been addressed. Below we discuss recent
evidence strongly implicating csCRT as an innate
immune system receptor that may play an impor-
tant role in the pathogenesis of RA.
The rheumatoid arthritis shared epitope
activates innate signaling through cell
surface calreticulin
Susceptibility to RA and the severity of the disease
are both closely associated with HLA-DRB1 alle-
les encoding a five amino acid sequence motif—
commonly referred to as the “shared epitope”
(SE)—in residues 70–74 of the DR chain.21 SE-
encoding DRB1 alleles confer higher risk of devel-
oping RA in most ethnic groups.22 Interestingly, de-
spite the strong influence of genetic factors on RA
susceptibility, the concordance rate in monozygotic
twins is only 12–15%,23 suggesting that stochastic
environmental or epigenetic factors are required to
precipitate disease onset in genetically susceptible
individuals. Consistent with this idea, epidemiolog-
ical studies in Europe24 and North America25 have
demonstrated interaction between smoking and the
SE: the presence of both factors resulted in a much
higher RA risk than the risk conferred by either
smoking or SE alone.
In addition to being a risk factor for RA, the SE
has also been shown to associate with disease sever-
ity.26 The disease in SE-positive individuals is more
erosive than in SE-negative individuals.27 In addi-
tion, the number of SE-encoding alleles has been
found to directly correlate with disease severity.28
The mechanism by which the SE increases suscep-
tibility to—and severity of—RA is unknown. The
known role of MHC class II molecules in antigen
presentation prompted the prevailing paradigms,
which postulate that either presentation of arthrito-
genic self-peptides,29 molecular mimicry with for-
eign antigens,30 or T cell repertoire selection31 are
involved. Notwithstanding their plausibility, these
hypotheses are difficult to reconcile with the fact that
data-supporting antigen-specific responses as the
primary event in RA are inconclusive. In addition,
several other human diseases have also been shown
to be associated with SE-encoding DRB1 alleles,
including polymyalgia rheumatica,32 giant cell ar-
teritis,32 type I diabetes,33 erosive bone changes in
psoriatic arthritis,34 autoimmune hepatitis,35 and
early-onset chronic lymphoid leukemia,36 among
other conditions. The SE has been also shown to
be associated with spontaneous RA-like disease in
dogs37 and to facilitate collagen-induced arthri-
tis,38 spontaneous diabetes,39 and experimental au-
toimmune encephalomyelitis40 in HLA-DRB1∗0401
transgenic mice. Furthermore, the increasing inci-
dence of RA with age41 and the positive correlations
observed between the number of copies of SE alle-
les and RA severity28 and disease penetrance42 are
all inconsistent with an antigen presentation-based
mechanism. Thus, taken together, these inconsis-
tencies suggest that the SE may have as yet un-
known antigen nonspecific effects independent of
the well documented role of class II MHC molecules
in antigen presentation. Our recent data reveal that
the SE may have a unique ability to activate in-
nate signaling events, which could lead to immune
dysregulation.
Given the inadequacies of antigen presentation-
based theories discussed earlier, over the past few
years we have examined whether the SE, similar to its
spatially homologous class I MHC ligands,43,44 can
trigger innate immune signaling. In all cases, our
prior studies have demonstrated that the SE could
activate nitric oxide (NO) signaling in a strictly
allele-specific manner. The SE was able to do this,
whether expressed in its native conformation on
the cell surface, as a cell-free HLA-DR tetrameric
molecule, engineered into large recombinant pro-
teins, or as a short synthetic peptide. A consen-
sus motif comprising of the 70Q/R-K/R-x-x-A74 se-
quence was found to be necessary for triggering the
signal.45–47
Mapping of the shared epitope-binding site
on calreticulin
We have previously identified csCRT as the cell
surface receptor that transduces the SE signal-
ing.48 In brief, affinity chromatography purifica-
tion, cell-binding assays, surface plasmon reso-
nance (SPR), and time-resolved fluorescence res-
onance energy transfer techniques identified csCRT
as the SE-binding molecule. SE-triggered signal-
ing could be blocked (by anti-CRT antibodies
or antibodies against CD91) and by CRT-specific
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anti-sense or small interfering RNA oligonu-
cleotides. Murine embryonic fibroblasts from
Crt−/− or cd91-deficient mice failed to transduce
SE-activated signals. Exogenously added soluble
CRT attached to the cell surface and restored sig-
naling responsiveness in Crt−/− cells.48
More recently, we have mapped the SE-binding
site on CRT.49 CRT has three domains: an N-
terminal domain, a C-terminal domain, and a mid-
dle domain called “P-domain.” To identify the
domain that binds the SE, we first determined SE-
CRT binding by SPR, using domain-selective dele-
tion mutants. These experiments strongly suggested
that the SE binding site is located in the P-domain.
The role of this domain as a SE-binding region was
further confirmed by a photoactive cross-linking
technique.49 To predict the interacting residues, the
BioMedCAChe 6.1 (Fujitsu, Sunnyvale, CA) in sil-
ico docking software was used. The ligand and the
receptor were modeled on the basis of the published
crystal structure of the SE within the native HLA-
DR molecule and published P-domain NMR-based
structural data, respectively. Four potential dock-
ing scenarios with significant energy were identified.
Intriguingly, region 217–224 of the CRT P-domain
was invariably found to be the SE-binding site in
all four docking models, with the most significant
roles played by amino acid residues E217, D220, and
E223 of the CRT P-domain.
To address the respective role of each one of these
candidate SE-binding P-domain residues, point-
mutants expressing single amino acid substitutions
have been used. Cell-free SPR binding assays where
the point-mutated CRT proteins were immobilized
on a biosensor chip and the SE peptides were in the
analyte, have shown a significantly diminished in-
teraction between the SE and CRT receptors that ex-
press E217A or E223A substitutions. Experiments to
determine the signal transduction efficiency of these
mutant receptors in a cell culture system demon-
strated that SE-expressing ligands activated signifi-
cantly diminished signals when the E217A, D220A,
or E223A CRT mutants were used as cell surface re-
ceptors, with the most significant role played by CRT
P-domain residue E217.49 Taken collectively, these
data indicates that the SE-binding site on CRT is lo-
cated in the 217–223 region in the P-domain, with
a critical role played by amino acid residue E217.
A proposed receptor–ligand interaction model is
shown in Figure 1.
Figure 1. CRT–SE interaction. A SE-positive HLA-DR4
molecule interacts with the SE-binding site in the CRT P-
domain. The HLA-DR chain is shown in green, the HLA-DR
chain is in yellow, the SE is in cyan, the CRT P-domain is in pink,
and the groove peptide is shown in orange.
Immune polarization by the shared epitope
As mentioned earlier, one of the hallmarks of
SE-induced csCRT-mediated signaling is the pro-
duction of NO, a ubiquitous signaling molecule
with versatile effects in the immune system. In
RA, increased NO levels correlate significantly with
inflammatory markers of the disease and anti-
rheumatic agents have been shown to suppress NO
production.50–52 NO has also been implicated in the
pathogenesis of experimental autoimmune models
in mice. For example, SJL mice are known for their
NO overproduction.53 These mice are susceptible
to many autoimmune diseases,54 and their autoim-
mune tendencies are attributed to their NO overpro-
duction.55 Similar to human RA, SJL mice display
aging-associated increase in disease incidence,56 ex-
cessive DNA damage,57 higher mutation rates,58 and
a higher incidence of spontaneous lymphoma.59
Thus, there is ample evidence that excessive NO
levels may facilitate autoimmunity.
Dendritic cells are professional antigen-
presenting cells strategically positioned in the
interface between the innate and adaptive immune
systems. Relevant to this review, csCRT is expressed
on both human and murine DCs.12 In human DCs,
a maturation-dependent expression was found,
with more abundant csCRT expression in imma-
ture DCs compared to mature cells.60 In addition
to their role in potentiating adaptive immune
responses, DCs also induce tolerance through a
variety of mechanisms, including a direct cross talk
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with regulatory T (Treg) cells.61 A growing body of
evidence indicates that the tolerogenic effect of DCs
is mediated partly by indoleamine 2,3 dioxygenase
(IDO), an enzyme that catalyzes the catabolism of
tryptophan.62
DCs play a key role in immune regulation and
are implicated in the pathogenesis of RA. Therefore,
we carried out studies to examine whether the SE
can activate innate signaling in murine DCs. Our
data clearly demonstrated that, similar to its ef-
fect in all other cell lines previously studied, the
SE activates NO signaling in murine DCs.63 Given
the fact that NO has been previously found to in-
hibit IDO activity,64–66 we have examined whether
SE-expressing ligands could affect IDO activity.63
Our data showed that cell-free SE-positive ligands
effectively and specifically blocked conversion of
tryptophan to kynurenine in DCs and fibroblasts.
Moreover, murine L cells expressing SE-positive DR
molecules on their surface through cDNA transfec-
tion produced significantly less kynurenine in re-
sponse to IFN , compared to transfectants express-
ing SE-negative DR chains. Thus, the SE ligand
effectively inhibits the activity of the tolerogenic en-
zyme IDO in both human and murine cells. We
have confirmed published observations67 that IDO
activity is found in DCs expressing the CD8 surface
marker but not in CD8− DCs and found that the
SE effect on IDO activity was restricted to that DCs
subset.63 While the mechanism of the dichotomy of
SE activity in the two subsets is presently unknown,
it is worth noting that the CD8+ subset showed
higher abundance of the SE signal transducing re-
ceptor, csCRT.63
In addition to IDO-mediated regulation, DCs can
regulate immune responses by production of vari-
ous cytokines that can activate or expand particular
subsets of T cells, thereby polarizing the immune
response.68 To determine whether SE-mediated sig-
naling in DCs could induce cytokine production,
we have studied supernatants of SE-stimulated DCs.
Our data showed that in the CD8− DCs, but not in
the CD8+ subset, the SE ligand activated a robust
production of IL-6. Although IL-23 levels did not
increase following stimulation with the SE alone, in
the presence of suboptimal concentrations of LPS,
the SE had a prolonged synergistic effect on the
production of this cytokine. Other cytokines did
not show any increased production, indicating the
specificity of SE effect.63
Consistent with the reciprocal effects of IDO and
IL-6 on Treg differentiation, we have demonstrated
that the SE ligand potently inhibited Treg differ-
entiation (Fig. 2). When DCs were pre-incubated
with the SE-positive peptide 65-79∗0401 Treg dif-
ferentiation was significantly inhibited, while SE-
negative control peptide 65-79∗0402 had no ef-
fect. Similar results were obtained using SE-positive
versus SE-negative HLA-DR tetramers.63 Thus,
the SE ligand has a potent inhibitory effect on
Treg.
As mentioned earlier, in CD8− DCs, the SE-
activated robust production of two Th17-activating
cytokines: IL-6 and IL-23. Th17 cells produce sev-
eral effector cytokines, which play important roles
in inflammation and autoimmunity, including, IL-
17A, IL-17F, IL-21, and IL-22.68 Over the past few
years, the Th17 subset has emerged as a key player
both in host defense and autoimmunity.69 There
is compelling evidence that Th17 cells may play a
direct role in the pathogenesis of RA. For exam-
ple, in RA, both IL-17-producing cells and IL-17
are abundantly expressed in the RA joint compart-
ment.70,71 In addition, IL-17 has been shown to in-
duce many factors known to enhance autoimmune
or pro-arthritogenic processes, such an angiogen-
esis, MMPs production, osteoclastogenesis, leuko-
cyte recruitment, angiogenesis and inflammation,
among other effects.72 Neutralization of IL-17 pre-
vents disease development in experimental mouse
models of autoimmunity.73,74
Consistent with its effect on DCs, the SE was
found to have a robust effect on Th17 differentia-
tion and expansion (Fig. 2), as well as activation of
proliferative responses and secretion of IL-17.63 Im-
portantly, the SE effect on Th17 polarization could
be seen both in vitro and in vivo.63 Taken together,
these findings indicate that the SE ligand, particu-
larly when presented in its native conformation, has
a potent Th17-polarizing effect.
A proposed model
Figure 3 shows a proposed model of CRT-mediated
SE effect in RA. In physiologic condition, DCs main-
tain a fine balance between immune stimulation
and tolerance. They are programmed to prevent
autoimmune reactions by responding to tolerance-
enhancing signals delivered either by Th1-derived
IFN or by CTLA4, expressed on Treg. These signals
activate IDO that increases tryptophan metabolites,
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Figure 2. T cell polarization by the SE. (A) DCs were incubated overnight without (medium) or with SE-positive (65-79∗0401) or
SE-negative (65-79∗0402) 15mer peptides. Subsequently, naive CD4 T cells were added and cocultured in the presence of TGF and
anti-CD3 antibodies. (B) Mean ± SEM values of triplicate flow cytometry determinations of the experiment shown in A. (C) Th17
polarization by the SE. DCs were cocultured with naive CD4 T cells in Th17-differentiating medium in the absence or presence of
SE-positive (65-79∗0401) or SE-negative (65-79∗0402) peptides. (D) DCs were incubated overnight with peptides or recombinant
hepatitis B core (HBc) particles containing the SE motif QKRAA (SE+) or a non-SE sequence DERAA (SE−) and then cocultured
with naive CD4 T cells as above. IL-17A concentrations in supernatants were determined by ELISA.
which preserve Treg-mediated immune tolerance.
The default setting of this intricate system assures a
well-balanced immune response and the prevention
of autoimmune reactions.
Figure 3. Proposed model. The SE is interacting with csCRT
expressed on DCs. As a result of a combined effect of IDO
inhibition on the one hand and production of Th17-polarizing
cytokines on the other, an immune regulation shift occurs with
reduced abundance of Tregs and enhanced Th17 differentiation.
In individuals carrying SE-encoding HLA-DRB1
alleles, the SE ligand, normally expressed on APC
or on lymphocytes, interacts with csCRT. Our
model states that in healthy SE-positive individu-
als SE-csCRT interaction activates low-grade signal-
ing with moderate Th17 polarization, which could
be advantageous against pathogens.69,75 However,
upon exposure to critical levels of environmental
pollutants (e.g., cigarette smoke), this beneficial po-
larization effect could become excessive owing to as
yet unknown stochastic events. Such aberrant inter-
action may lead to excessive Th17 polarization that
allows the development of RA. It should be pointed
out that excessive Th17 polarization has been pre-
viously shown in mice following exposure to en-
vironmental aromatic hydrocarbons76 and the SE
has been shown to synergize with cigarette smoking
as a risk factor for RA.24,25 It is therefore tempting
to entertain a scenario in which the SE and envi-
ronmental pollutants may cooperatively push Th17
polarization beyond a threshold that allows RA
development.
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